CRDL Cardiol Therapeutics Inc.
USHealthcareAs of 2026-07-10 16:00
Why CRDL matters now
Cardiol Therapeutics Inc. (CRDL) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.01 with +1.81% on the session and $116.4M in market capitalization; recent performance reads 1-month -15.87% and YTD +11.13%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.8M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -14.0%.
The latest indexable market news headline is "Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.78
P/S
0.00
EV/EBITDA
-4.14
DCF Value
$0.18
FCF Yield
-14.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-229.2%
ROA
-115.7%
ROIC
-146.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.8M | $-0.10 |
| Q4 2025 | $0.00 | $-7.2M | $-0.07 |
| FY 2025 | $0.00 | $-33.8M | $-0.39 |
| Q3 2025 | $0.00 | $-10.0M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.00
Target (Median)
$8.00
Target Range
$8.00 - $8.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
CA
Exchange
—
Beta
0.80
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.